Hematology Service, Hospital Clínico San Carlos, C/Profesor Martín Lagos s/n, 28040, Madrid, Spain.
Instituto de Investigación Sanitaria Hospital Clínico San Carlos, Madrid, Spain.
Ann Hematol. 2022 Jul;101(7):1465-1471. doi: 10.1007/s00277-022-04837-4. Epub 2022 Apr 25.
Most β-thalassemias are caused by mutations involving one or a limited number of nucleotides within the gene or its adjacent regions. They can be substitutions or deletions; in these cases, the loss ranges from a single nucleotide to even the entire HBB gene, so we wonder if the phenotype is due to the size of the deletion or the location of the mutation. To clarify this, we present two new deletions in the β-globin gene that cause β-thalassemia. The hematological parameters were determined with an automated cell counter; the Hb A2 and Hb F levels were measured by performance liquid chromatography. Hemoglobins were analyzed by capillary zone electrophoresis (Sebia Capillarys Flex system) and ion-exchange HPLC (BioRad Variant II β-thalassemia Short Program). Molecular characterization was performed by automatic Sanger sequencing. The screening of common α-thalassemia point mutations and deletions in the world (21 in total) were carried out using multiplex PCR followed by reverse-hybridization with a commercial Alpha-Globin StripAssay kit. We have characterized two new mutations-(1) 1-bp deletion [CD61/62(-G)] [HBB:c.186_187delG], (2) 105-bp deletion [IVS-2-nt767-CD111] [HBB:c.316-84_333del]-and we have described, for first time in Spain, the 25-bp deletion [β nts 252 - 276 deleted] [HBB:c.93-22_95del] mutation. These mutations were classified as pathogenic by UniProt Variants confirmed according to the American College of Medical Genetics and Genomics guidelines. These mutations present a phenotype compatible with β-thalassemia, supported by hematological parameters that correlate the degree of reduction in the synthesis of the β-globin chain. Identification of this type of mutation is important for genetic counselling of partners where both are carriers, so that they are aware of the genetic risk of having affected children, allowing them to take an informed decision about their reproductive choices.
大多数β-地中海贫血是由于基因或其相邻区域内一个或有限数量的核苷酸发生突变引起的。这些突变可以是替换或缺失;在这些情况下,缺失范围从单个核苷酸到整个 HBB 基因,因此我们想知道表型是由于缺失的大小还是突变的位置引起的。为了澄清这一点,我们介绍了两种导致β-地中海贫血的新的β-珠蛋白基因突变。使用自动细胞计数器测定血液学参数;通过高效液相色谱法测定 HbA2 和 HbF 水平。血红蛋白通过毛细管区带电泳(Sebia Capillarys Flex 系统)和离子交换 HPLC(BioRad Variant II β-地中海贫血短程序)进行分析。分子特征通过自动 Sanger 测序进行。采用多重 PCR 结合商业 Alpha-Globin StripAssay 试剂盒进行反向杂交,对世界范围内常见的α-地中海贫血点突变和缺失(共 21 种)进行了筛查。我们已经鉴定了两种新的突变-(1) 1bp 缺失 [CD61/62(-G)] [HBB:c.186_187delG],(2) 105bp 缺失 [IVS-2-nt767-CD111] [HBB:c.316-84_333del]-并首次在西班牙描述了 25bp 缺失 [β 核苷酸 252-276 缺失] [HBB:c.93-22_95del]突变。这些突变根据美国医学遗传学与基因组学学院的指南,经 UniProt 变体证实,被归类为致病性。这些突变表现出与β-地中海贫血一致的表型,血液学参数支持β-珠蛋白链合成减少的程度。鉴定这种类型的突变对于双方都是携带者的伴侣的遗传咨询很重要,这样他们就可以意识到生育受影响孩子的遗传风险,使他们能够就其生殖选择做出明智的决定。